For instance, a phase II clinical trial in HER2-negative breast cancer patients demonstrated that the combination of bevacizumab (an anti- vascular endothelial growth factor (VEGF)-A antibody) with adriamycin/cyclophosphamide/paclitaxel chemotherapy exhibited vascular normalization effects and was associated with tumor regression44. Here, VEGFA is linked to breast carcinoma.